At a Glance
7
R&D Sites in the US and China
2,500+
Employees Globally
450+
Global IND Packages Completed
100+
Global NDA Packages Completed
30
Clinical Centers in China
10+
Years GMP and GLP Lab Experience
430+
Validated Methods for Bioanalysis
Integrated Testing Platforms
Preclinical Drug Development
WuXi IND (WIND) combines technical experience, program management and regulatory expertise to facilitate submission of your IND package.
Clinical Drug Development
The Laboratory Testing Division can carry your compound from early discovery all the way through clinical trials, providing consistent, streamlined support across the lifecycle of your project.
Medical Device Testing
WuXi’s medical device testing experts provide end-to-end regulatory and technical support to bring your medical devices to market.
End-to-End Services
Analytical Services
The Analytical Services Unit provides both early and late-phase analytical support, including integrated CMC services from IND to NDA and beyond.
Bioanalytical Services
Bioanalytical Services at the Laboratory Testing Division support in vitro ADME, discovery biology, PK, PD and discovery toxicology from NCE through IND.
DMPK Services
The Laboratory Testing Division provides comprehensive in vitro and in vivo ADMET solutions from high-throughput screening in discovery through drug development phases.
Toxicology Services
Our skilled team of toxicologists provide comprehensive safety assessments across a wide range of species and through various routes of administration.
Highlights
WuXi Laboratory Testing Division: Propelling Innovation and Better Treatments for Patients
Read our thought leadership article “Creating Comprehensive Solutions through Laboratory Testing”
WuXi Experts Opinion on Impurity Research During Drug Development Webinar
September 6
1:30pm Eastern
4th Congress of the European Societies of Toxicology (EUROTOX 2018)
September 2 – 5
Brussels, Belgium